Induced pluripotent stem cells in research and therapy

Malaysian Journal of Pathology

Volumn 34, Issue 1, 2012, Pages 1-13

  Teoh, Hoon Koon ^a,c   Cheong, Soon Keng ^b,c  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Disease modelling; Embryonic like properties; Gene therapy; Patient specific therapy; Regenerative medicine

Indexed keywords

KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; LIN 28 PROTEIN; MICRORNA; MICRORNA 200C; MICRORNA 302S; MICRORNA 369S; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; VALPROIC ACID;

CELL RENEWAL; CELL THERAPY; DISEASE MODEL; DRUG DEVELOPMENT; GENE EXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SICKLE CELL ANEMIA; SOMATIC CELL; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

ALPHA 1-ANTITRYPSIN DEFICIENCY; ANEMIA, SICKLE CELL; ANIMALS; CELL DIFFERENTIATION; CELL TRANSPLANTATION; DRUG DISCOVERY; FANCONI ANEMIA; GENE THERAPY; HEMOPHILIA A; HUMANS; INDIVIDUALIZED MEDICINE; INDUCED PLURIPOTENT STEM CELLS; MICE; REGENERATIVE MEDICINE;

EID: 84863310681     PISSN: 01268635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
2. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-20.
3. Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963;197: 452-4.
4. Friel R, van der Sar S, Mee PJ. Embryonic stem cells: understanding their history, cell biology and signalling. Adv Drug Deliv Rev 2005;57:1894-903.
5. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7.
6. Glover C. Human embryonic stem cells. Stem cell Technologies newsletter 2008.
7. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyteprogenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005;25:4694-705.
8. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients fromALS can be differentiated into motor neurons. Science 2008;321:1218-21.
9. Yang D, Zhang ZJ, Oldenburg M, et al. Multiple layers of molecular controls modulate self-renewal and neuronal lineage specification of embryonic stem cells. Stem Cells 2008; 26:55-63.
10. McLaren A. Human embryonic stem cell lines: socio-legal concerns and therapeutic promise. C R Biologies 2002;325:1009-12.
11. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
12. Stadfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-9.
13. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-53.
14. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-5.
15. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-4.
16. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-6.
17. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008;26:1276-84.
18. Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood 2009;113:5476-9.
19. Lowry WE, Richter L, Yachechko R, et al. eneration of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA 2008;105:2883-8.
20. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008;26:1269-75.
21. Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic β cells into induced pluripotent stem cells. Curr Biol 2008;18:890-4.
22. Somers A, Jean JC, Sommer CA, et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28:1728-40.
23. Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011;8;376-88.
24. Maherali N, Ahfeldt T, Rigamonti A, et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008;3:340-5.
25. Stadtfeld M, Maherali N, Breault DT, et al. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008;2:230-40.
26. Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol 2010;10:81.
27. Woltjen K, Michael IP, Mohseni P, et al. piggyback transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-70.
28. Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad 2009;85:348-62.
29. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30.
30. Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011;8: 633-8.
31. Cowan CA, Atienza J, Melton DA, et al. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005;309:1369-73.
32. Han J, Sachdev PS, Sidhu KS. A combined epigenetic and non-genetic approach for reprogramming human somatic cells. PLoS One 2010;5(8): e12297.
33. Nsair A, MacLellan WR. Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery. Adv Drug Deliv Rev 2011;63:324-30.
34. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008;105:5856-61.
35. Oh YZ, Wei HM, Ma DR, et al. Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart 2012;98(6):443-9.
36. Zhang N, An MC, Montoro D, et al. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr 2010;2:RRN1193.
37. Zhang JQ, Lian QZ, Zhu GL, et al. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011;8:31-45.
38. Liu GH, Barkho BZ, Ruiz S, et al. Recapitulationof premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011;472(7342):221-5.
39. Urbach A, Bar-Nur O, Daley GQ, et al. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010;6(5):407-11.
40. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008;134(5):877-86.
41. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397e409.
42. Matsa E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:952e62.
43. Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood 2010;115:4039-42.
44. Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2010;107(1):40-45.
45. Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012:1-14.
46. Pessach IM, Ordovas-Montanes J, Zhang SY, et al. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol 2011;127(6):1400-7.
47. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-6.
48. US Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Available from: http://wwwfdagov/oc/initiatives/criticalpath/whitepaperhtml, March 2004.
49. Chun YS, Chaudhari P, Jang YY. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease (review). Int J Biol Sci 2010;7:796-805.
50. Braam SR, Mummery CL. Human stem cell models for predictive cardiac safety pharmacology. Stem Cell Res 2010;4(3)155-6.
51. Otsuji TG, Kurose Y, Yamauchi K, et al. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: qualitative effects on electrophysiological responses to drugs. Stem Cell Res 2010;4(3):201-13.
52. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461(7262):402-6.
53. O'Connor TP, Crystal RG. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet 2006;7:261-76.
54. Zwaka TP. 2009. In Stem Cell Information [World Wide Web site]. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services, 2009 [cited Sunday, April 15, 2012] Available at http://stemcells.nih.gov/info/scireport/2006chapter4.
55. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6.
56. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58.
57. Capecchi MR. Altering the genome by homologous recombination. Science 1989;244:1288-92.
58. Pessach IM, Notarangelo LD. Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction. J Allergy Clin Immunol 201;127:1344-50.
59. Durai S, Mani M, Kandavelou K, et al. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 2005;33:5978-90.
60. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318(5858):1920-3.
61. Pawliuk R, Westerman KA, Fabry ME, et al. Correction in sickle cell disease in transgenic mouse models by gene therapy. Science 2001;294:2368-71.
62. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478:391-4.
63. Fakharzadeh SS, Zhang Y, Sarkar R, et al. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 2000;95:2799-805.
64. Kung SH, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998;91:784-90.
65. Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009;106(3):808-13.
66. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010;362:1909-19.
67. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001;2:446-57.
68. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001;7:241-8.
69. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
70. Galimi F, Noll M, Kanazawa Y, et al. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood 2002;100:2732-6.
71. Raya A, Rodriguez-Piza I, Navarro S, et al. A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Nat Protoc 2010;5(4): 647-60.
72. Eminli S, Utikal J, Arnold K, et al. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 2008;26:2467-74.
73. Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 2008;41(1):51-6.
74. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471(7336):63-7.
75. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-18.
76. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011;471(7336):68-73.
77. Pestina TI, Hargrove PW, Jay D, et al. Correction of murine sickle cell disease using γ-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther 2009;17(2):245-52.
78. Ye ZH, Zhan HC, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009;114:5473-80.
79. Alipio Z, Liao WB, Roemer EJ, et al. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic β-like cells. Proc Natl Acad Sci USA 2010;107(30):13426-134-31.
80. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010;120:3127-36.
81. Ghodsizadeh A, Taei A, Totonchi M, et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev 2010; 6:622-32.
82. Kawagoe S, Higuchi T, Meng XL, et al. Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells. Mol Genet Metab 2011;104:123-8.
83. Zhang SQ, Chen S, Li W, et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet 2011;20(16):3176-87.
84. Tolar J, Park IH, Xia L, et al. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood 2011;117:839-47.
85. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457(7227):277-80.
86. Marchetto MCN, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-39.
87. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473(7346):221-7.
88. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-77.
89. Byers B, Cord B, Nguyen HN, et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One 2011;6(11):e26159.
90. Nori S, Okada Y, Yasuda A, et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci USA 2011;108(40):16825-30.
91. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012;482(7384):216-20.
92. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010;465(7299):808-12.
93. Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471(7337):230-4.
94. Batista LF, Pech MF, Zhong MF, et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011;474(7351):399-402.
95. Jin ZB, Okamoto S, Osakada F, et al. Modeling retinal degeneration using patient-specific induced pluripotent stem cells. PLoS One 2011;6:e17084.
96. Itoh M, Kiuru M, Cairo MS, et al. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci USA 2011;108(21):8797-802.